MedPath

Reprixys Pharmaceutical Corporation

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

Phase 2
Completed
Conditions
Sickle Cell Disease
Interventions
Drug: Placebo
First Posted Date
2013-07-10
Last Posted Date
2020-01-31
Lead Sponsor
Reprixys Pharmaceutical Corporation
Target Recruit Count
198
Registration Number
NCT01895361

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.